- recruitingPHASE1, PHASE2
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
This study is looking at a new medicine called revumenib for different types of leukaemia that have come back or not responded to treatment. It aims to find the right dose and see how well it works and if it's safe for people with certain genetic changes in their leukaemia.
United States · Australia · Canada - recruitingPHASE3
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
This study looks at a new drug called blinatumomab for babies under one year old with a specific type of leukaemia (blood cancer). The aim is to make treatments better for these tiny patients by adding blinatumomab to their usual care. It's a key step in finding more effective ways to fight this illness.
Argentina · Australia · Austria - recruitingPHASE1, PHASE2
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
This study looks at blood and bone marrow from children and young people with leukaemia that's come back or is hard to treat. It helps doctors understand the leukaemia better, which could lead to improved treatments and new ways to diagnose and care for young patients.
United States · Australia · Canada - active not recruitingPHASE1, PHASE2
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
This study is testing a new drug called ziftomenib for people with a type of blood cancer called acute myeloid leukaemia (AML) that has come back or not responded to previous treatments. It's the first time this drug is being used in people.
United States · Belgium · Canada